ReviewClinical and translational medicine2018
Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti-tuberculosis activity.
Review in Clinical and translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Analysis of Quality Differences inFood science & nutrition · 2026Article
- Quinoline analogs: multifaceted heterocyclic compounds with varied synthetic strategies and potent antitubercular properties.RSC advances · 2025Review
- Bioinformatics-driven untargeted metabolomic profiling for clinical screening of methamphetamine abuse.Forensic toxicology · 2025Article
- Elucidating the Phytochemical Landscape of Leaves, Stems, and Tubers ofMolecules (Basel, Switzerland) · 2024Article
- Discovery of pyrimidine-tethered benzothiazole derivatives as novel anti-tubercular agents towards multi- and extensively drug resistantJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Biomarker discovery for tuberculosis using metabolomics.Frontiers in molecular biosciences · 2023Review
- Tao-Hong-Si-Wu decoction improves depressive symptoms in model rats via amelioration of BDNF-CREB-arginase I axis disorders.Pharmaceutical biology · 2022Article
- Article
- Metabolomics Signatures and Subsequent Maternal Health among Mothers with a Congenital Heart Defect-Affected Pregnancy.Metabolites · 2022Article
- Novel Potential Diagnostic Serum Biomarkers of Metabolomics in Osteoarticular Tuberculosis Patients: A Preliminary Study.Frontiers in cellular and infection microbiology · 2022Article
- β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward.Frontiers in microbiology · 2022Review
- Article
- Deciphering the mechanism of action of antitubercular compounds with metabolomics.Computational and structural biotechnology journal · 2021Review
- Secondary Metabolism and Hormone Response Reveal the Molecular Mechanism of Triploid Mulberry (Frontiers in plant science · 2021Article
- A Review on Recent Trends in Green Synthesis of Gold Nanoparticles for Tuberculosis.Advanced pharmaceutical bulletin · 2021Review
- Omics for Bioprospecting and Drug Discovery from Bacteria and Microalgae.Antibiotics (Basel, Switzerland) · 2020Review
- Plant Secondary Metabolites in the Battle of Drugs and Drug-Resistant Bacteria: New Heroes or Worse Clones of Antibiotics?Antibiotics (Basel, Switzerland) · 2020Review
- Untargetted Metabolomic Exploration of theBiomolecules · 2020Article
- Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era.Frontiers in microbiology · 2020Review
- Ethnobotany, ethnopharmacology, and phytochemistry of traditional medicinal plants used in the management of symptoms of tuberculosis in East Africa: a systematic review.Tropical medicine and health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human tuberculosis (TB) is amongst the oldest and deadliest human bacterial diseases that pose major health, social and economic burden at a global level. Current regimens for TB treatment are lengthy, expensive and ineffective to emerging drug resistant strains. Thus, there is an urgent need for identification and development of novel TB drugs and drug regimens with comprehensive and specific mechanisms of action. Many medicinal plants are traditionally used for TB treatment. While some of their phytochemical composition has been elucidated, their mechanisms of action are not well understood. Insufficient knowledge on Mycobacterium tuberculosis (M.tb) biology and the complex nature of its infection limit the effectiveness of current screening-based methods used for TB drug discovery. Nonetheless, application of metabolomics tools within the 'omics' approaches, could provide an alternative method of elucidating the mechanism of action of medicinal plants. Metabolomics aims at high throughput detection, quantification and identification of metabolites in biological samples. Changes in the concentration of specific metabolites in a biological sample indicate changes in the metabolic pathways. In this paper review and discuss novel methods that involve application of metabolomics to drug discovery and the understanding of mechanisms of action of medicinal plants with anti-TB activity. Current knowledge on TB infection, anti-TB drugs and mechanisms of action are also included. We further highlight metabolism of M. tuberculosis and the potential drug targets, as well as current approaches in the development of anti-TB drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.